Cleveland Clinic's Sydell and Arnold Miller Family Heart & Vascular Institute is one of the largest cardiovascular and thoracic specialty groups in the world. Experts provide the latest in medical and surgical care, all enhanced by advanced technology, research and education. It has been ranked No. 1 in America for heart care for 21 years in a row. The Miller Family Heart & Vascular Institute is one of 27 institutes at Cleveland Clinic, a nonprofit, academic medical center ranked among the nation's top hospitals (U.S. News & World Report), where more than 3,200 staff physicians and researchers in 120 specialties collaborate to give every patient the best outcome and experience.

To learn more about Cleveland Clinic's Miller Family Heart & Vascular Institute, visit **clevelandclinic.org/heart**.



The Cleveland Clinic Foundation 9500 Euclid Avenue, JJ40 Cleveland, OH 44195

Cleveland Clinic



EUROPEAN SOCIETY OF CARDIOLOGY - SATELLITE SYMPOSIUM CVD Risk Reduction and Lipid Management: State of the Science

COMPLIMENTARY LUNCH SYMPOSIUM

Monday, August 29, 2016 12:45-13:45 Nicosia – Village 1 Rome, Italy

PROGRAM OVERVIEW

This activity has been designed to provide focused education and practical guidance on the management of dyslipidemia in the modern era. The content will highlight the limitations of statin therapy and the residual risk of cardiovascular disease and summarize clinical trial data for current and future therapeutic options in managing dyslipidemia.

LEARNING OBJECTIVES

- 1) Identify patient populations who continue to be at elevated cardiovascular risk despite use of standard lipid-lowering therapy
- 2) Assess the impact of LDL-C reduction and improving HDL functionality in reducing cardiovascular risk in patients with complex dyslipidemias, statin intolerance, and familial hypercholesterolemia
- 3) Evaluate the pharmacology, safety, and efficacy of therapeutic agents that target CETP
- 4) Describe the physiology of high-density lipoprotein (HDL) and treatments targeting HDL

Supported by an independent sponsorship from Eli Lilly and Company

COURSE DIRECTORS

Leslie Cho, MD Cleveland Clinic Cleveland, OH

FACULTY

Leslie Cho. MD Cleveland Clinic

Cleveland Clinic

Cleveland Clinic Cleveland, OH

Katherine Hoercher, RN

John J.P. Kastelein, MD, PhD University of Amsterdam

Steven Nissen, MD Cleveland Clinic

A. Michael Lincoff, MD

AGENDA MONDAY, AUGUST 29, 2016 | 12:45-13:45

CHAIR: Leslie Cho, MD

12:45	Unmet Medical Needs With Current Agents and Residual CV Risk: Rationale for Developing New Agents Steven Nissen, MD
13:00	New Horizons for the Statin Intolerant Patients: Current and Future Therapeutic Options Leslie Cho, MD
13:15	Prospects for Clinical Benefit with CETP Inhibition in Light of Current and Future Trials A. Michael Lincoff, MD
13:30	The Science of HDL and Reverse Cholesterol Transport – Are We Still Hopeful? John J.P. Kastelein, MD, PhD
13:45	Adjourn

NOTES